Komori
Occurring Fact4591RIBOMIC Inc.Medicines

Notice of achievement of the enrollment target in the domestic Phase III clinical trial of the achondroplasia treatment umedaptanib pegol

Enrollment of 18 subjects in the domestic Phase III clinical trial of umedaptanib pegol has been completed, exceeding the planned target of 16 subjects. Including subjects who have already provided consent, the final enrollment may reach a maximum of 25 subjects.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
18
Enrolled subjects (target: 16)
Wording
Conditional
How definitive the wording is.

Achievement of the target number of subjects in the domestic Phase III clinical trial of the achondroplasia treatment umedaptanib pegol (WAKABA study)

Subject Entity

RIBOMIC Inc. (filing company)

Target Locations / Products

Participating medical institutions nationwide, umedaptanib pegol (RBM-007), WAKABA study, pediatric patients with achondroplasia (2–14 years old)

Occurrence17 November 2026 (18 subjects enrolled as of this date)
This disclosure11/17/2026
Cause

Because subject enrollment was conducted at participating medical institutions nationwide

Amount of Impact on Business Performance

Amount: Not disclosed. The impact on full-year results for the fiscal year ending March 2027 is minor

Accounting period in which recognized

Full year ending March 2027 (the impact on results from this matter is minor)

Impact on Earnings Forecast

The impact of this matter on full-year results for the fiscal year ending March 2027 is minor

Outlook

Subjects who provided consent during the consent period are scheduled to be enrolled by the end of November 2026, and the final number of enrolled subjects may reach a maximum of 25. The company will continue to conduct the WAKABA study and advance development toward obtaining early approval for umedaptanib pegol.

Event that occurred
ItemDetails
Event nameAchievement of the target number of subjects in the domestic Phase III clinical trial of the achondroplasia treatment umedaptanib pegol (WAKABA study)
Date of occurrence17 November 2026 (18 subjects enrolled as of this date)
Subject EntityRIBOMIC Inc. (filing company)
Target Locations / ProductsParticipating medical institutions nationwide, umedaptanib pegol (RBM-007), WAKABA study, pediatric patients with achondroplasia (2–14 years old)
CauseBecause subject enrollment was conducted at participating medical institutions nationwide
Amount of Impact on Business PerformanceAmount: Not disclosed. The impact on full-year results for the fiscal year ending March 2027 is minor
Accounting period in which recognizedFull year ending March 2027 (the impact on results from this matter is minor)
Impact on Earnings ForecastThe impact of this matter on full-year results for the fiscal year ending March 2027 is minor
OutlookSubjects who provided consent during the consent period are scheduled to be enrolled by the end of November 2026, and the final number of enrolled subjects may reach a maximum of 25. The company will continue to conduct the WAKABA study and advance development toward obtaining early approval for umedaptanib pegol.
Items this document does not state (16)
Date recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explains that, after enrolling the first subject in July 2026, it proceeded with subject enrollment at participating medical institutions nationwide and achieved the target number of subjects as planned. It expects the enrollment above the target to contribute to the accumulation of more comprehensive clinical data.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of achievement of the enrollment target in the domestic Phase III clinical trial of the achondroplasia treatment umedaptanib pegol | RIBOMIC Inc. (4591) timely disclosure | Komori